Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Zillow Group Inc Class A — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.39 (market cap $9.43B), while Zillow Group Inc Class A trades at $33.31 (market cap $7.68B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| BIO | ZG | |
|---|---|---|
Market Cap | $9.43B | $7.68B |
Sector | Health | Media |
52-Week High | $356.25 | $86.76 |
52-Week Low | $241.71 | $29.14 |
Enterprise Value | $9.18B | $7.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Zillow Group (ZG) trades at $32.97, down 3.23% today, reflecting near-term pressure amid a securities class action deadline. The stock shows a bearish technical signal with support at $32 and resistance at $35. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years, though valuation ratios like a P/E of 149 indicate high expectations. Recent Q2 2026 earnings beat expectations with 18% revenue growth, driven by the Preferred Agent model.
The outlook is mixed: analyst consensus is a Buy with a $47.56 price target, suggesting 44% upside, but risks include legal overhangs from the class action and a high P/E requiring sustained growth. Investors should weigh the bullish monetization shift against near-term volatility and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
